linjc16/ctgov huggingface dataset:
Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

Study Overview
=================
Brief Summary
-----------------
Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.

Detailed Description
-----------------
Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic dehydrogenase release from lysed cells.

Official Title
-----------------
Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy

Conditions
-----------------
Melanoma, Kidney Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center Patients must sign and give written informed consent in accordance with institutional and federal guidelines Exclusion Criteria: Patients not undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with melanoma or kidney cancer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| LAK cytotoxicity |  | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Interleukin-2, Melanoma, Kidney Cancer, Lymphokine Activated Killer cells
The CCUS Based Characteristic of Hemodynamic and Lung Pathology in Early Stage of Shock in ICU: The Epidemic and Prognostic Value

Study Overview
=================
Brief Summary
-----------------
Shock is a common condition in critical care unit (ICU). It is extremely important that the patient accepts early goal-directed therapy (EGDT) treatment in the early stage of shock. However, several studies failed to demonstrate that the well used variables such as CVP and others could direct to a better treatment. In recent years, critical care ultrasound (CCUS) has been respected as a reliable noninvasive tool and widely used in ICU practice. With CCUS the investigators can accurately acquired the detailed information of the characteristic of the hemodynamics and lung pathology (the systole and diastole function, volume status, valve insufficiency, lung, edema, consolidation, and pleural effusion, etc.). To the investigators knowledge, there is no study investigating the epidemic of such ultrasonic variables and its value to predict to outcome. The aim of this study is to investigate the epidemic and the prognostic value of CCUS Based Characteristic of Hemodynamic and Lung pathology in Early Stage of Shock in patients admitted in ICU.

Detailed Description
-----------------
Adult patients who admitted to the intensive care unit of West China hospital of sichuan university with shock from April 2016 to April 2017 enrolled.

Official Title
-----------------
The Critical Care Ultrasound Based Characteristic of Hemodynamic and Lung Pathology in Early Stage of Shock in ICU: The Epidemic and Prognostic Value

Conditions
-----------------
Shock

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: SBP<90 mm Hg or MAP <70 mm Hg or SBP decrease >40mmHg or need vasoactive drugs; Skin that is cold and clammy, capillary refill time >4.5s, urine output of <0.5ml/Kg.hr and lactate>2mmol/L; SHOCK presented within 6 hr. Exclusion Criteria: <18 years old; Pregnancy; Patient or family member refuse to be enrolled.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause mortality |  | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of mechanical ventilation |  | through study completion, an average of 28 days | 
| ICU length of stay |  | through study completion, an average of 28 days | 
| hospital length of stay |  | through study completion, an average of 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
shock, critical care ultrasound, hemodynamics, lung pathology, epidemic, prognosis
Prostate Cancer Prospective Cohort

Study Overview
=================
Brief Summary
-----------------
The overall purpose of this research is to determine if certain genes increase the chance of developing prostate cancer and once diagnosed increase the chance of the prostate cancer spreading to other parts of the body.

Detailed Description
-----------------
DNA will be isolated from each person and then studied for the presence of certain genes that may increase the chance of developing prostate cancer. Certain genes will also be studied in patients with known prostate cancer to determine if they increase the chance of cancer spreading to other parts of the body and decrease one's chance of being cured. Small differences in genes can slightly affect their ability to function. While these differences are normal, they may influence the way the cancer responds to therapy. An understanding of which genes increase (or decrease) the chance of being cured of a disease, such as prostate cancer, will improve our ability to take care of patients more effectively. A second purpose of this study is to collect blood and cancer tissue for future studies. While the small differences in genes may be the best marker of bad cancer, it is also possible that proteins in blood or tumor may be a better marker.

Official Title
-----------------
Prostate Cancer Prospective Cohort

Conditions
-----------------
Prostate Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed patients: 1. newly diagnosis of prostate cancer 2. untreated except for neoadjuvant systemic therapy. Exclusion Criteria: Newly diagnosed patients: 1. inability to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Newly diagnosed patients<br>Patients with newly diagnosed prostate cancer. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability to recognize increased risk of metastatic prostate cancer based on specific genetic polymorphisms. |  | At the time of prostate cancer diagnosis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability to predict risk for treatment failure based on analysis of specific polymorphisms. |  | At the time of prostate cancer diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metastatic Prostate Cancer, Prostate Cancer Risk Assessment
the Role of Gum Chewing in Regaining Bowel Motility in Patients Undergoing Cesarean Section

Study Overview
=================
Brief Summary
-----------------
Aim:to evaluate the efficacy of postoperative gum chewing on the recovery of bowel motility after cesarean section.

Detailed Description
-----------------
this study will be conducted on 162 patients undergoing cesarean section in obstetrics and gynecology department at Kasr el Ainy Hospital,Kairo university.

Official Title
-----------------
The Role of Sugarless Gum Chewing in Regaining Bowel Motility in Patients Undergoing Cesarean Section

Conditions
-----------------
Effect of Gum Chewing on Regaining Bowel Motility After Cesarean Section

Intervention / Treatment
-----------------
* Drug: sugarless gum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-35 --Spinal anesthesia Pfannensteil incision Exclusion Criteria: History of drug consumption especially opioids water and electrolyte disturbance History of abdominal surgery except cesarean section Intra and severe post operative complications diabetes Pre-eclampsia Hypothyroidism Muscular and neurological disorder Inability to chew gums

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 81 patients,group 1<br>81 women will receive 1 stick of sugarless gum for 15 minutes every 2 hours after surgery . | Drug: sugarless gum<br>* 81 patients will receive 1 stick of sugarless gum(Samara gum) for 15 minutes every 2 hours<br>* Other names: Samara Gum;|
| No Intervention: 81 patients,group 2<br>81 patients will have traditional management(oral intake of clear fluids after hearing of first intestinal sounds or passage of flatus and regular diet after passage of stool) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| first bowel sound in hours |  | 4-6 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| first passage of flatus in hours,the first defecation in hours |  | 4-6 hours |
PAncreatic Adenocarcinoma in Hospital

Study Overview
=================
Brief Summary
-----------------
Few data are currently available in the literature on pancreatic adenocarcinoma in France. About 8,000 new cases each year in France. The 5-year survival for all stages combined is <5%. This is the only digestive cancer in which mortality / incidence ratio is 98%. Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life. The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country. The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.

Official Title
-----------------
PAncreatic Adenocarcinoma in Hospital

Conditions
-----------------
Pancreatic Adenocarcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Living in France Pancreatic adenocarcinoma histologically or cytologically proven primary diagnosis Agreed to participate Exclusion Criteria: Suspected pancreatic adenocarcinoma histologically or cytologically unproven Refused to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pancreatic Adenocarcinoma<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival |  | patient death (following during 5 year) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pancreatic adenocarcinoma, diagnosis, treatment
Diagnosis Test for Gestational Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
Gestational diabetes mellitus (GDM) is an asymptomatic disease. Diagnosis is based on a oral glucose tolerance test (OGTT) requiring pregnant women to absorb 75g of glucose while fasting since midnight and to stay sober for another two hours. These OGTTs are poorly tolerated by pregnant women. As many OGTT are false positive according to self-monitoring blood glucose (SMBG), the investigators need now to determine the percentage of OGTT results that are false negative. The comparison of the two tests (OGTT and SMBG) in the same patient with normal results of OGTT will determine the exact percentage of false negative OGTT results. The opinion of women will also be taken into account. In the everyday clinic, many report that they prefer SMBG to OGTT because they do not have to be fasting, to drink non palatable drink and to attend a 2-hour visit in their schedule. However, no opinion study has yet been performed, the investigators will investigate formally what women think using a questionnaire.

Official Title
-----------------
Assessment of the Diagnosis Test for Gestational Diabetes Mellitus

Conditions
-----------------
Gestational Diabetes Mellitus

Intervention / Treatment
-----------------
* Procedure: Diagnosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: positive GDM screening test (glycemia post-50g of glucose ≥ 7.2 mmol/L), between 24 and 28 weeks of gestation from the last menstruation, single pregnancy, able to read and understand French. Exclusion Criteria: known type 1 or type 2 diabetes, disease or treatment interfering with the metabolism of glucose, deficiency may hinder the understanding of the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proportion of OGTTs falsely negative |  | Will be evaluated when participants finished SMBG i.e. 7 days after the OGTT | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| preference of participants regarding the two tests (OGTT vs. SMBG) | Evaluated by questionnaire | Will be evaluated when participants finished SMBG i.e. 7 days after the OGTT | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diagnosis
Prostate Cancer Screening in Men With Germline BRCA2 Mutations

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the incidence of prostate cancer in men with the BRCa2 gene mutation as an independent indicator for prostate cancer screening.

Detailed Description
-----------------
This is a cohort screening study to prospectively identify the incidence of prostate cancer in a population of BRCA2 carriers. All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing. Standard of care screening at the Yale Cancer Center for men with a normal prostate cancer risk consists of a PSA test and prostate physical examination beginning at age 50 years and if either is abnormal an MRI of the prostate followed by Fusion-targeted biopsy of the prostate is performed.

Official Title
-----------------
Prostate Cancer Screening in Men With Germline BRCA2 Mutations

Conditions
-----------------
Prostate Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All men ≥30 years of age with at least a ten-year life expectancy A known BRCA2 mutation Ability to have an MRI Able to give informed consent will be approached to participate in the study Exclusion Criteria: If a man has received or is currently receiving treatment for prostate cancer

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| BRCA2 Carriers<br>All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Prostate Cancer Patients With BRCA2 Mutation Carriers | number of patients with a BRCA2 mutation who are diagnosed with prostate cancer | Up to 3 years |
Clinical Validation of the Rating Scale for Psychotic Depression (RAS-PD)

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to develop a scale to measure the severity of depression with psychotic symptoms (psychotic depression). Furthermore, we hope to detect potential biomarkers (substances in the blood) which can aid in the detection of psychotic depression. Main hypothesis: A clinically valid rating scale measuring the severity of psychotic depression can be developed.

Conditions
-----------------
Affective Disorders, Psychotic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fulfilling ICD-10 criteria DF32.3 or DF33.3 At least 18 years old Legally competent Informed consent (oral & written) Exclusion Criteria: Insufficient Danish Language skills Moderate to severe dementia Abuse of psychoactive substances

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Affective Disorders, Psychotic, Psychometrics, Biological Markers
Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7-Ag

Study Overview
=================
Brief Summary
-----------------
The study aims to: Achieve molecular imaging of MG7 antigen in patients with gastric cancer in vivo using confocal laser endomicroscopy. Compare the results of in vivo MG7-specific molecular imaging with CLE and ex vivo immunohistochemistry .

Detailed Description
-----------------
Gastric cancer remains the world's second leading cause of cancer-related death. Improved prognosis essentially depend on earlier diagnosis. Gastric monoclonal antibody MG7 has been validated as a specific antibody in gastric cancerous tissue. Conventional evaluation of MG7 antigen expression is immunohistochemistry, which is time-consuming, and the immunoreactivity can be affected by storage and fixation of tissue. Confocal laser endomicrosopy enables visualization of the cellular and subcellular structures in vivo. Thus this study aims to achieve molecular imaging of MG7 antigen in gastric cancer in vivo using confocal laser endomicroscopy.

Official Title
-----------------
Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7 Antigen

Conditions
-----------------
Gastric Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with endoscopically diagnosed gastric cancer Exclusion Criteria: Patients who are allergic to fluorescein sodium Patients who are unwilling to sign or give the informed consent form Patients with giant tumors or obvious GI tract bleeding which make it hard or impossible to observe the lesions Patients with impaired cardiac, liver or renal function Patients with coagulopathy Patients with pregnancy or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Glucose Variability With DPP-4 Inhibition

Study Overview
=================
Brief Summary
-----------------
Glucose Variability With DPP-4 Inhibition

Detailed Description
-----------------
Patients with Type 2 Diabetes, age 35-75y., will be included in this double blind randomized placebo controlled study. The sample size of 50 patients completing the 30 day study period is based on statistical input from Merck Research Laboratories, Rahway NJ.

Official Title
-----------------
Glucose Variability With DPP-4 Inhibition

Conditions
-----------------
Type 2 Diabetes

Intervention / Treatment
-----------------
* Drug: Sitagliptin, placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes receiving a stable dose of metformin ≥ 1500 mg HbA1c 7,5% -10/0 % Exclusion Criteria: Type 1 diabetes HbA1c < 7,5% and > 10,0%

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: sitagliptin, metformin, placebo<br>group- 25 patients will take sitagliptin 50 mg and metformin 1000 mg twice in a day group- 25 patients will take placebo 50 mg and metformin 1000 mg twice in a day | Drug: Sitagliptin, placebo<br>* sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day<br>* Other names: Januvia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glucose variability |  | 1 month |